Bou-Gharios G, Adams G, Pace P, Olsen I
Cell Enzymology Unit, Kennedy Institute of Rheumatology, Bute Gardens, London, UK.
J Inherit Metab Dis. 1992;15(6):899-910. doi: 10.1007/BF01800230.
This study uses bone marrow transplantation (BMT) between congenic strains of mice as an experimental model to examine enzyme replacement therapy of lysosomal storage diseases. Bone marrow cells from donor mice which have normal levels of the lysosomal enzyme beta-glucuronidase (Gus), which is heat-stable, rapidly repopulated the haematopoietic compartment of irradiated recipient mice which have only low levels of a thermolabile form of this enzyme. Gus activity was found to increase progressively in the tissues of the recipients, including the liver, heart and skeletal muscle. Elevated levels were also observed in the kidney and brain. The increase in enzyme activity in the host tissues was not due to the presence of contaminating blood cells, but rather to the acquisition of new, heat-stable enzyme from the donor bone marrow cells. High levels of Gus activity persisted for at least 72 weeks, showing the potential therapeutic value of BMT for enzyme deficiency diseases.
本研究采用同基因品系小鼠之间的骨髓移植(BMT)作为实验模型,以检验溶酶体贮积病的酶替代疗法。来自供体小鼠的骨髓细胞具有正常水平的溶酶体酶β-葡萄糖醛酸酶(Gus),该酶耐热,能迅速重新填充受辐照受体小鼠的造血区室,这些受体小鼠仅具有低水平的这种酶的不耐热形式。发现Gus活性在受体的组织中逐渐增加,包括肝脏、心脏和骨骼肌。在肾脏和大脑中也观察到活性升高。宿主组织中酶活性的增加不是由于污染血细胞的存在,而是由于从供体骨髓细胞获得了新的、耐热的酶。高水平的Gus活性持续至少72周,显示了BMT对酶缺乏疾病的潜在治疗价值。